Cardiotoxicity associated with trastuzumab in normal clinical practice;Cardiotoxicidad asociada a trastuzumab en la práctica clínica asistencial

Farmacia Hospitalaria

Volumn 33, Issue 4, 2009, Pages 202-207

  Vicente, C ^a   Serrano, N ^a   Agustin M J ^a   Alonso, V ^a   Palomo, P ^a   Huarte, R ^a  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Adverse effects; Cardiotoxicity; HER2 breast cancer; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; ARTICLE; ASTHENIA; BREAST CANCER; CARDIOTOXICITY; CLINICAL PRACTICE; COMPUTER PROGRAM; CONGESTIVE HEART FAILURE; DRUG SAFETY; DYSPNEA; FEMALE; FEVER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYALGIA; RESPIRATORY TRACT INFECTION; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HEART DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 70349470791     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1130-6343(09)72165-8     Document Type: Editorial

References (20)

1. O. Yavas, M. Yazici, O. Eren, and B. Oyan The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients Swiss Med Wkly 137 2007 556 558 (Pubitemid 47582838)
2. A. Lin, and H.S. Rugo The role of trastuzumab in early stage breast cancer: current data and treatment recommendations Curr Treat Options Oncol 8 2007 47 60
3. R.H. Engel, and V.G. Kaklamani HER2-positive breast cancer: current and future treatment strategies Drugs 67 2007 1329 1341 (Pubitemid 46879097)
4. Herceptin® (trastuzumab). Ficha técnica. Madrid: Roche Farma; 2005.
5. C.A. Hudis Trastuzumab -mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51 (Pubitemid 47026733)
6. G.A. Viani, S.L. Afonso, E.J. Stefano, L.I. De Fendi, and F.V. Soares Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
7. K. McKeage, and C.M. Perry Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2 Drugs 62 2002 209 243 (Pubitemid 34169431)
8. M.S. Ewer, H.R. Gibbs, J. Swafford, and R.S. Benjamin Cardiotoxicity in patients receiving trastuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artefact? Semin Oncol 26 1999 96 101 (Pubitemid 29411439)
9. J.D. Floyd, D.T. Nguyen, R.L. Lobins, Q. Basir, D.C. Doll, and M.C. Perry Cardiotoxicity of cancer therapy J Clin Oncol 23 2005 7685 7696
10. National Library for Health-News & RSS Article. Long-term herceptin use poses "acceptable" cardiac risk. [Accedido 13 Ene 2008]. Disponible en: http//www.library.nhs.uk/rss/newsAndRssArticle.aspx
11. T.M. Suter, M. Procter, D.J. Van Veldhuisen, M. Muscholl, J. Bergh, and C. Carlomagno Trastuzumab-associated cardiac adverse effects in the Herceptin Adyuvant Trial J Clin Oncol 25 2007 3859 3865 (Pubitemid 47477261)
12. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith The Herceptin Adyuvant (HERA) Trial Study Team Trastuzumab after adyuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
13. V. Guarneri, D.J. Lenihan, V. Valero, J.B. Durand, K. Broglio, and K.R. Hess Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD Anderson Cancer Center Experience J Clin Oncol 24 2006 4107 4115 (Pubitemid 46622286)
14. H.L. McArthur, and S. Chia Cardiotoxicity of trastuzumab in clinical practice N Engl J Med 357 2007 94 95
15. F. Montemurro, S. Redana, G. Valabrega, R. Martinello, M. Aglietta, and R. Palmiero Trastuzumab-related cardiotoxicity in the Herceptin Adyuvant Trial J Clin Oncol 26 2008 2052 2053
16. M.L. Telli, S.A. Hunt, R.W. Carlson, and A.E. Guardino Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility J Clin Oncol 25 2007 3525 3533 (Pubitemid 47310891)
17. M. Ewer, M.T. Vooletich, J.B. Durand, M.L. Woods, J.R. Davis, and V. Valero Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 23 2005 7820 7826 (Pubitemid 46657379)
18. P.P. Sengupta, D.W. Northfelt, F. Gentile, J.L. Zamorano, and B.K. Khandheria Trastuzumab-induced cardiotoxicity: heart failure at the crossroads Mayo Clin Proc 83 2008 197 203 (Pubitemid 351303103)
19. E.A. Perez, and R. Rodeheffer Clinical cardiac tolerability of trastuzumab J Clin Oncol 22 2004 322 329 (Pubitemid 41095098)
20. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)